Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / CCL5



This biomarker is also known as:
  • small inducible cytokine subfamily A (Cys-Cys), member 5,
  • chemokine (C-C motif) ligand 5,
  • TCP228,
  • SIS-delta,
  • EoCP,
  • small inducible cytokine A5 (RANTES),
  • Eosinophil chemotactic cytokine,
  • T-cell specific protein p288,
  • eoCP,
  • SISd,
  • eosinophil chemotactic cytokine,
  • T cell-specific protein P228,
  • t cell-specific protein P228,
  • MGC17164,
  • small-inducible cytokine A5,
  • C-C motif chemokine 5,
  • SCYA5,
  • D17S136E,
  • regulated upon activation, normally T-expressed, and presumably secreted,
  • beta-chemokine RANTES,
  • Small-inducible cytokine A5,
  • T-cell-specific protein RANTES,

View in BioMuta


CCL5 (RANTES) is a chemokine, a subfamily of cytokines. Chemokines form a superfamily of secreted proteins involved in immunoregulatory and inflammatory processes. CCL5 is a chemoattractant for blood monocytes, memory T-helper cells and eosinophils and causes the release of histamine from basophils and activates eosinophils. There are several transcript variants that encode different isoforms.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Under Review


The chemokine CCL5 (RANTES), a major monocyte chemoattractant expressed by breast tumor cells, has been implicated in the progression of breast cancer.

Performance Comment

CCL5 (RANTES) was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2015 Steering Committee Meeting

The next EDRN Steering Committee Meeting will take place March 31st through April 2nd, 2015, in Atlanta, Georgia.

Announcement 12/02/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh ( no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.